Alere to Develop Simple, Affordable Point-of-Care Nucleic Acid Test for Tuberculosis
Tuesday, March 05, 2013
Alere Inc. announced that it has been awarded a grant of up to $21.6 million and debt financing of up to $20.6 million from the Bill & Melinda Gates Foundation.
Lab21 and IntegraGen Partner
Tuesday, March 05, 2013
Lab21 Limited has entered into an agreement with IntegraGen to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.
Newly Launched RIQAS Website Makes EQA Even Simpler for Laboratories Worldwide
Monday, March 04, 2013
www.riqas.com allows users to easily discover the many benefits offered by the world’s largest External Quality Assessment (EQA) scheme, Randox International Quality Assessment Scheme (RIQAS) and the advantages of implementing EQA in their laboratory.
Humedics Starts LiMAx Phase III Trial on Liver Function Analysis for Severe Liver Surgery
Monday, March 04, 2013
First patients being included directly after study initiation in Berlin and Jena.
Theorem Clinical Research Distributes Clinical Trial Advice
Thursday, February 28, 2013
Company releases booklets to provide ICH GCP guidance for in vitro and investigational product trials.
Capturing Cancer Cells
Thursday, February 28, 2013
When dealing with cancer, time is critical. Identifying cancer before it spreads can often be the difference between life and death, so early diagnosis is key.
Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine
Wednesday, February 27, 2013
Adds former LabCorp leader Thomas Mac Mahon to board of directors, expects further growth in 2013.
Cancer Genetics, Inc. Receives Regulatory Approvals for MatBA®-DLBCL
Wednesday, February 27, 2013
MatBA®-DLBCL is a proprietary microarray test for the diagnosis, prognosis, and patient risk stratification of non-Hodgkin Lymphoma.
Lab21 and IntegraGen Partner to Develop New Colorectal Cancer Diagnostic
Tuesday, February 26, 2013
Lab21 to develop a CE marked assay to detect expression levels of a microRNA biomarker.
|
|
|
|
|
|
